Overview

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)

Status:
Not yet recruiting

Trial end date:
2025-07-23

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

Rozanolixizumab